Login to Your Account



Other News To Note


Wednesday, June 26, 2013
• Twi Biotechnology Inc., of Taipei, Taiwan, said it completed enrollment in a Phase II trial of AC-201 for gout flare prophylaxis during urate-lowering therapy (ULT). The randomized study includes patients with acute arthritis of primary gout and elevated serum uric acid.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription